Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,435 as of Friday, May 16, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,512 issues advancing vs. 1,401 declining with 184 unchanged. The Health Care sector currently sits down 0.8% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include NPS Pharmaceuticals ( NPSP), down 5.0%, InterMune ( ITMN), down 5.0%, Isis Pharmaceuticals ( ISIS), down 4.8%, Incyte ( INCY), down 4.6% and Seattle Genetics ( SGEN), down 4.2%. Top gainers within the sector include Intuitive Surgical ( ISRG), up 1.8%, Regeneron Pharmaceuticals ( REGN), up 1.4%, CR Bard ( BCR), up 1.1%, Agilent Technologies ( A), up 1.0% and Thermo Fisher Scientific ( TMO), up 0.8%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Illumina ( ILMN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Illumina is down $2.60 (-1.8%) to $142.15 on light volume. Thus far, 502,244 shares of Illumina exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $140.60-$146.00 after having opened the day at $145.74 as compared to the previous trading day's close of $144.75. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $18.6 billion and is part of the drugs industry. Shares are up 30.9% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.